treosulfan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastic, alkylating agents, methanesulfonates 2718 299-75-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • treosulfan
  • threosulphan
  • treosulphan
  • tresulfan
  • trecondi
immunosuppressant; RN given refers to (S-(R*,R*))-isomer
  • Molecular weight: 278.29
  • Formula: C6H14O8S2
  • CLOGP: -2.20
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 127.20
  • ALOGS: -1.21
  • ROTB: 7

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 97 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.59 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.90 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.83 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 20, 2019 EMA medac Gesellschaft fur klinische Spezialpraparate mbH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Adenovirus infection 185.43 79.87 35 1047 2795 46682185
Graft versus host disease in skin 172.33 79.87 32 1050 2335 46682645
Cytomegalovirus infection 125.21 79.87 36 1046 18108 46666872
Human herpesvirus 6 infection 109.49 79.87 22 1060 2417 46682563
Varicella zoster virus infection 104.37 79.87 21 1061 2322 46682658
Acute graft versus host disease in skin 99.32 79.87 21 1061 2961 46682019
Mucosal inflammation 94.44 79.87 35 1047 38941 46646039

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection 263.37 64.27 81 1440 23593 29927364
Graft versus host disease in skin 179.62 64.27 40 1481 3267 29947690
Adenovirus infection 164.23 64.27 39 1482 4229 29946728
Graft versus host disease in gastrointestinal tract 149.63 64.27 34 1487 3035 29947922
Mucosal inflammation 143.85 64.27 55 1466 30439 29920518
Acute graft versus host disease in skin 111.86 64.27 29 1492 4487 29946470
Epstein-Barr virus infection 66.04 64.27 21 1500 6685 29944272
Human herpesvirus 6 infection 65.48 64.27 16 1505 1942 29949015

Pharmacologic Action:

SourceCodeDescription
ATC L01AB02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Alkyl sulfonates
MeSH PA D000477 Alkylating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018906 Antineoplastic Agents, Alkylating
MeSH PA D009676 Noxae

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Allogeneic peripheral blood stem cell transplant indication 425843001

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D07253 KEGG_DRUG
C5418135 UMLSCUI
CHEBI:82557 CHEBI
CHEMBL455186 ChEMBL_ID
C018404 MESH_SUPPLEMENTAL_RECORD_UI
3103 INN_ID
DB11678 DRUGBANK_ID
CO61ER3EPI UNII
9296 PUBCHEM_CID
8281 IUPHAR_LIGAND_ID
38508 RXNORM
004465 NDDF
326774002 SNOMEDCT_US
395912000 SNOMEDCT_US

Pharmaceutical products:

None